Clinical Trial Update: A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 trial evaluates the safety and tolerability of a single dose of MKC253 inhalation powder in healthy adult male volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MKC253 (MKC253)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 2, Healthy Males | Phase 1 | Status: COMPLETED